Fluoroquinolones vs β-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: A meta-analysis of randomized controlled trials

Mayo Clinic Proceedings

Volumn 81, Issue 12, 2006, Pages 1553-1566

  Falagas, Matthew E ^a,b,c   Matthaiou, Dimitrios K ^a   Vardakas, Konstantinos Z ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFAMANDOLE; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FLEROXACIN; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; OFLOXACIN; OXACILLIN; PEFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIMENTIN; VANCOMYCIN;

ARTICLE; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOCOMPETENCE; META ANALYSIS; NAUSEA; SKIN ABSCESS; SKIN INFECTION; SKIN ULCER; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; WOUND INFECTION;

EID: 33845310882     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.12.1553     Document Type: Article

References (75)

1. Lewis RT. Soft tissue infections. World J Surg. 1998;22:146-151.
2. File TM Jr, Tan JS. Treatment of bacterial skin and soft tissue infections. Surg Gynecol Obstet. 1991;172(suppl):17-24.
3. Elston DM. Epidemiology and prevention of skin and soft tissue infections. Cutis. 2004;73(5, suppl):3-7.
4. Bisno AL. Cutaneous infections: microbiologic and epidemiologic considerations. Am J Med. 1984;76(5A):172-179.
5. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs. 2004;64:1621-1642.
6. Parsad D, Pandhi R, Dogra S. A guide to selection and appropriate use of macrolides in skin infections. Am J Clin Dermatol. 2003;4:389-397.
7. Miller EL. The penicillins: a review and update. J Midwifery Womens Health. 2002;47:426-434.
8. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt). Fall 2005;6:283-295.
9. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs. 2003;63:1459-1480.
10. von Rosenstiel N, Adam D. Quinolone antibacterials: an update of their pharmacology and therapeutic use [published correction appears in Drugs. 1994;48:326]. Drugs. 1994;47:872-901.
11. Sorgel F, Kinzig M. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections. Eur J Surg Suppl. 1994;573:39-44.
12. Walstad RA, Hellum KB, Thurmann-Nielsen E, Dale LG. Pharmacokinetics and tissue penetration of Timentin: a simultaneous study of serum, urine, lymph, suction blister and subcutaneous thread fluid. J Antimicrob Chemother. 1986;17(suppl C):71-80.
13. LaRosa SP, Tomecki KJ. Antibiotics: what's new? Cutis. 2004;73(5, suppl):10-14.
14. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med. 1996;156:661-666.
15. Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials: current issues and future directions. Int J Technol Assess Health Care. Spring 1996;12:195-208.
16. Tarshis GA, Miskin BM, Jones TM, et al. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother. 2001;45:2358-2362.
17. Lipsky BA, Miller B, Schwartz R, et al. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections. Clin Ther. 1999;21:675-690.
18. Nicodemo AC, Robledo JA, Jasovich A, Neto W. A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract. 1998;52:69-74.
19. Nichols RL, Smith JW, Gentry LO, et al. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South Med J. 1997;90:1193-1200.
20. Drehobl M, Koenig L, Barker M, St Clair P, Maladorno D. Fleroxacin 400 mg once daily versus ofloxacin 400 mg twice daily in skin and soft tissue infections. Chemotherapy. 1997;43:378-384.
21. Parish LC, Jungkind DL. Systemic antimicrobial therapy in skin and skin structure infections: comparison of temafloxacin and ciprofloxacin. Am J Med. 1991;91(6A):115S-119S.
22. Siami G, Christou N, Eiseman I, Tack KJ, Severe Skin and Soft Tissue Infections Study Group. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother. 2001;45:525-531.
23. Neldner KH. Double-blind randomized study of oral temafloxacin and cefadroxil in patients with mild to moderately severe bacterial skin infections. Am J Med. 1991;91(6A):111S-114S.
24. Fass RJ, Plouffe JF, Russell JA. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. Am J Med. 1989;87(5A):164S-168S.
25. Huston MJ, Lentino JR. Intravenous fleroxacin versus ceftazidime for lower respiratory tract and skin and soft-tissue infections. Clin Ther. 1992;14:595-602.
26. Nicolle LE, Degelau J, Alessi P, Cullison J, Meyers B. Ofloxacin use in a geriatric population. Chemotherapy. 1991;37(suppl 1):49-54.
27. Quintero-Perez NP, Andrade-Villaneuva JF, Leon-Garnica G, Bertin-Montano M, Rodriguez-Chagollan JJ, Rodriguez-Noriega E. Efficacy and safety of intravenous ciprofloxacin in the treatment of serious infections: a comparison with ceftazidime. Am J Med. 1989;87(5A):198S-201S.
28. Partsch DJ, Paladino JA. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy. Ann Pharmacother. 1997;31:1137-1145.
29. Lubowski TJ, Nightingale C, Sweeney K, Quintiliani R, Zhi J. Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study. Antimicrob Agents Chemother. 1992;36:651-655.
30. Lonsky V, Dominik J, Mand'ak J, et al. Changes of the serum antibiotic levels during open heart surgery (ceftazidim, ciprofloxacin, clindamycin). Acta Medica (Hradec Kralove). 2000;43:23-27.
31. Brunner M, Stabeta H, Moller JG, et al. Target site concentrations of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 2002;46:3724-3730.
32. Winston DJ, Lazarus HM, Beveridge RA, et al. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis. 2001 Feb 1;32:381-390. Epub 2001 Jan 30.
33. Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol. 2000;34:87-91.
34. Johnson PR, Liu Yin JA, Tooth JA. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother. 1992;30:203-214.
35. Johnson PR, Yin JA, Tooth JA. High dose intravenous ciprofloxacin in febrile neutropenic patients. J Antimicrob Chemother. 1990;26(suppl F):101-107.
36. Dawe RS, Ibbotson SH, Sanderson JB, Thomson EM, Ferguson J. A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br J Dermatol. 2003;149:1232-1241.
37. Ferguson J, McEwen J, Al-Ajmi H, Purkins L, Colman PJ, Willavize SA. A comparison of the photosensitizing potential of trovafloxacin with that of other quinolones in healthy subjects. J Antimicrob Chemother. 2000;45:503-509.
38. Vousden M, Ferguson J, Richards J, Bird N, Allen A. Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin. Chemotherapy. 1999;45:512-520.
39. Meyerhoff C, Dilger C, Yoon SJ, et al. Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. J Antimicrob Chemother. 1998;42:349-361.
40. Ferguson J, Dawe R. Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin. J Antimicrob Chemother. 1997;40(suppl A):93-98.
41. Lowe NJ, Fakouhi TD, Stern RS, Bourget T, Roniker B, Swabb EA. Photoreactions with a fluoroquinolone antimicrobial: evening versus morning dosing. Clin Pharmacol Ther. 1994;56:587-591.
42. Liu HH, Bolash NK, McAnany ME, Lynch RA. Susceptibility of bacterial isolates from complicated skin and skin structure infections to cefazolin, imipenem-cilastatin, ciprofloxacin and ofloxacin. Drugs. 1995;49(suppl 2):215-218.
43. Bojar RA, Hittel N, Cunliffe WJ, Holland KT. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs. 1995;49(suppl 2):164-167.
44. Sesso R, Parisio K, Dalboni A, et al. Effect of sodium fusidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol. 1994;41:370-376.
45. Baiocchi P, Venditti M, Santini C, et al. Alterations of coagulase-negative staphylococcal flora in cardiac surgery patients: comparative study between cefamandole and pefloxacin perioperative prophylaxis. J Chemother. 1989;1:305-309.
46. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med. 1991;91:462-470.
47. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents. 2005 Nov;26:357-365. Epub 2005 Oct 17.
48. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis. 2002 Aug 15;35:381-389. Epub 2002 Jul 19.
49. Parish LC, Routh HB, Miskin B, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract. 2000;54:497-503.
50. Krumpe PE, Cohn S, Garreltes J, et al, Ciprofloxacin Study Group. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. J Antimicrob Chemother. 1999;43(suppl A):117-128.
51. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis. 1997;24:643-648.
52. Parish LC, Jungkind DL. Systemic antimicrobial therapy for skin and skin structure infections: comparison of fleroxacin and ceftazidime. Am J Med. 1993;94(3A):166S-173S.
53. Powers RD. Open trial of oral fleroxacin versus amoxicillin/clavulanate in the treatment of infections of skin and soft tissue. Am J Med. 1993;94(3A):155S-158S.
54. Smith JW, Nichols RL. Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections. Am J Med. 1993;94(3A):150S-154S.
55. Tassler H. Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections. Am J Med. 1993;94(3A):159S-165S.
56. Lipsky BA, Yarbrough DR III, Walker FB IV, Powers RD, Morman MR. Ofloxacin versus cephalexin for treating skin and soft tissue infections. Int J Dermatol. 1992;31:443-445.
57. Powers RD, Schwartz R, Snow RM, Yarbrough DR III. Ofloxacin versus cephalexin in the treatment of skin, skin structure, and soft-tissue infections in adults. Clin Ther. 1991;13:727-736.
58. Powers RD. Soft tissue infections in the emergency department: the case for the use of 'simple' antibiotics. South Med J. 1991;84:1313-1315.
59. Dominguez J, Palma F, Vega ME, et al. Prospective, controlled, randomized non-blind comparison of intravenous/oral ciprofloxacin with intravenous ceftazidime in the treatment of skin or soft-tissue infections. Am J Med. 1989;87(5A):136S-137S.
60. Gallis HA, Brennan RO, Goodwin SD, Swinney V, Rumbaugh MM, Drew RH. Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections. Am J Med. 1989;87(5A):176S-180S.
61. Gentry LO, Koshdel A. Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure. Am J Med. 1989;87(5A):132S-135S.
62. Gentry LO, Ramirez-Ronda CH, Rodriguez-Noriega E, Thadepalli H, del Rosal PL, Ramirez C. Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections: a multicenter trial. Arch Intern Med. 1989;149:2579-2583.
63. Gentry LO, Rodriguez-Gomez G, Zeluff BJ, Khoshdel A, Price M. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am J Med. 1989;87(6C):57S-60S.
64. Villavicencio J, Asensio de Fernandez ME, Ramirez CA. Intravenous ciprofloxacin or ceftazidime in selected infections: a prospective, randomized, controlled study. Am J Med. 1989;87(5A):191S-194S.
65. Ramirez-Ronda CH, Saavedra S, Rivera-Vazquez CR. Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections. Am J Med. 1987;82(4A):220-223.
66. Parish LC, Asper R. Systemic treatment of cutaneous infections: a comparative study of ciprofloxacin and cefotaxime. Am J Med. 1987;82(4A):227-229.
67. Chulavatnatol S, Chindavijak B, Vibhagool A, Wananukul W, Sriapha C, Sirisangtragul C. Pharmacokinetics of levofloxacin in healthy Thai male volunteers. J Med Assoc Thai. 1999;82:1127-1135.
68. Gentry LO. Therapy with newer oral beta-lactam and quinolone agents for infections of the skin and skin structures: a review. Clin Infect Dis. 1992;14:285-297.
69. Joseph WS. Staphylococcal resistance and oral cephalosporins for skin and skin structure infections. Cutis. 2004;73(5, suppl):19-20.
70. Appelbaum PC, Jacobs MR. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr Opin Microbiol. 2005;8:510-517.
71. MacDougall C, Harpe SE, Powell JP, Johnson CK, Edmond MB, Polk RE. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis. 2005;11:1197-1204.
72. Jones ME, Schmitz FJ, Fluit AC, Acar J, Gupta R, Verhoef J, SENTRY Participants Group. Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Programme. Eur J Clin Microbiol Infect Dis. 1999;18:403-408.
73. Bhavnani SM, Callen WA, Forrest A, et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. Am J Health Syst Pharm. 2003;60:1962-1970.
74. Mohr JF, Jones A, Ostrosky-Zeichner L, Wanger A, Tillotson G. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. Int J Antimicrob Agents. 2004;24:346-351.
75. Bogdanovich T, Esel D, Kelly LM, et al. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents. Antimicrob Agents Chemother. 2005;49:3325-3333.